Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EVAXBullishIndustry Newsnews

High materiality8/10

EVX-01 three-year phase 2 data to debut at ESMO 2026

Jul 17, 2026, 7:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive phase 2 signals with high ORR and durable responses could improve EVAX's valuation and attract interest from partners; ESMO data cadence adds near-term upside but requires confirmation from later-stage results.

AI summary

What happened, with direct paths to the underlying reporting

Evaxion will unveil three-year efficacy data for EVX-01 in advanced melanoma at ESMO 2026, including a stand-alone third-year arm. Early two-year results showed strong responses and durability, suggesting meaningful potential for standalone use and future partnerships if durability holds through longer follow-up.

EVX-01 three-year phase 2 data to be presented at ESMO 2026; third-year stand-alone arm.
Two-year data: ORR 75% (12/16) with 4 complete responses; 92% durability.
86% of targeted neoantigens elicited T-cell responses; 15/16 tumor reductions observed.
54% deepened responses during treatment; data may inform durability and potential partnerships.
Presentation abstract 2006P on Oct 24, 2026, Hall 5, CET 12:00-12:45.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.